Previous 10 | Next 10 |
PALO ALTO, Calif. , April 2, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the appointment of Charles Bancroft to its board of director...
Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Outperform rating and $54 (88% upside) price target at BMO. More news on: Apellis Pharmaceuticals, Inc., Arena Pharmaceuticals, Inc., HEXO Corp., Healthcare stocks news, Stocks on the move, , Read more ...
For all those who missed the train in 2019, the coronavirus pandemic has presented another chance to pick up Kodiak Sciences ( KOD ) stock. Let us see, what makes the company a solid buy at these share price levels. Company overview Founded in 2009, Kodiak Sciences is a clinical-stage bi...
I am constantly looking to provide valuable information to my readers on how to outperform the market while taking few risks. A very strong strategy to outperform the market is following insider purchases, as literature has proven that this strategy could beat the market by as much as 24.20% p...
Market Pulse This week all the major indexes made new lows. The market continues to be under stress and this is not the final low. Biotechs were one of the few industry groups that didn't make a new low this week. A respite from non-stop selling will come from the economic stimulus package w...
PALO ALTO, Calif. , March 24, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that the company received full registration of thei...
InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...
Healthcare Pulse A new reality dawned as the stock market entered a bear market. It wasn't a tiptoe moment for the bear. The market simply plummeted into a bear market canyon. Just from March 4 to March 12, in about a week, the S&P 500 and Nasdaq declined 20% or more. The healthcare ...
Kodiak Sciences (NASDAQ: KOD ): Q4 GAAP EPS of -$0.40 misses by $0.03 . More news on: Kodiak Sciences Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
PALO ALTO, Calif. , March 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for the fo...
News, Short Squeeze, Breakout and More Instantly...
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform PR Newswire Tarcocimab clinical and non-clinical data high...
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 14.4% to $1.04 on volume of 163,835,451 shares S&P 500 ETF TRUST ETF (SPY) fell 0.0% to $523.07 on volume of 96,294,886 shares Gamida Cell Ltd. (GMDA) fell 39.0% to $0.0361 on volume of 89,181,214 sh...
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 14.4% to $1.04 on volume of 163,835,451 shares S&P 500 ETF TRUST ETF (SPY) fell 0.0% to $523.07 on volume of 96,294,886 shares Gamida Cell Ltd. (GMDA) fell 39.0% to $0.0361 on volume of 89,181,214 sh...